| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
2 This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, relating to our business, operations, and financial conditions, in... |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 |
| 08 Jul 2026 |
Form 4: Souza Marcio, Director
Gave 23,121 shares as a gift |
| 07 Jul 2026 |
8-K: Other Events
On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of electronically controlled... |
| 02 Jul 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated June 29, 2026, of Praxis Precision Medicines, Inc. and are in agreement with the statements contained in the second, third and fourth paragraphs. We have no basis to agree or disagree with other s... |
| 29 Jun 2026 |
8-K: Other Events
On June 29, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application ... |
| 26 Jun 2026 |
Form 4: DeSimone Jill, Director
Received 11,600 shares by exercise or conversion ($826K) · Sold 11,600 shares ($3.61M) |
| 24 Jun 2026 | 144 |
| 22 Jun 2026 |
8-K: Other Events
On June 22, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of sei... |
| 12 Jun 2026 |
Form 4: Arbuckle Stuart A, Director
Received 1,371 shares as a grant or award · Granted 648 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Chodakewitz Jeffrey, Director
Received 1,371 shares as a grant or award · Granted 648 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Young William D, Director
Received 1,371 shares as a grant or award · Granted 648 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: DeSimone Jill, Director
Received 1,371 shares as a grant or award · Granted 648 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Mitchell Dean J, Director
Received 1,371 shares as a grant or award · Granted 648 Stock Option (Right to Buy) |
Loading...